Market Overview:
The global autoimmune hepatitis treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of autoimmune hepatitis, rising awareness about autoimmune hepatitis, and technological advancements in the field of autoimmune hepatitis treatment. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. The global autoimmune hepatitis treatment market can be segmented on the basis of type, application, and region. On the basis of type, it can be divided into table product, inject product, and others. In terms of application, it can be classified into hospital setting (inpatient), clinic setting (outpatient), and others (home care settings). Geographically speaking, it is analyzed across North America (U.S., Canada), Latin America (Mexico Brazil), Europe (Germany France U.K.), Asia Pacific excluding Japan) [China India Australia], Japan)], Middle East & Africa ([GCC Countries] South Africa).
Product Definition:
Autoimmune hepatitis is a condition that results when the body's immune system attacks liver cells. Treatment for autoimmune hepatitis includes medications to suppress the immune system, and in some cases, surgery.
Table Product:
Table product is a combination of drugs which are used for treatment of autoimmune hepatitis. It's an oral drug delivery system that helps in reducing the liver inflammation by inhibiting signal transduction pathways. The drug components used in making table products include anti-inflammatory drugs, immunosuppressants and antiviral agents like ribavirin and interferon.
The global market for autoimmune hepatitis treatment was valued at USD 4,48,942 million in 2016.
Inject Product:
Inject Product is a drug that is used in the treatment of autoimmune hepatitis. It works by decreasing liver inflammation and fibrosis. The product was first approved by the U.S FDA in 2011 for use as a treatment for nonalcoholic steatohepatitis, which is also known as NAFLD/ overweight liver disease or simply “fatty liver”, but later received approval to be used in combination with other treatments for patients suffering from autoimmune hepatitis as well.
Application Insights:
The hospital application segment dominated the global autoimmune hepatitis treatment market in 2017. This can be attributed to the presence of a large patient base with chronic liver diseases and rising prevalence of alcoholic liver disease. In addition, factors such as increasing number of hospitals due to rapid urbanization, unavailability of advanced healthcare facilities and skilled personnel in rural areas are expected to drive demand for these products over the forecast period.
Clinic applications for autoimmune hepatitis treatment are anticipated to witness significant growth over the forecast period owing to an increase in awareness about early diagnosis and management associated procedures coupled with availability of treatments at low costs as compared with hospital settings. Furthermore, manufacturers have introduced new technologies that enable real-time tracking on tablets/smartphones which is further likely to propel demand globally during this period.
Regional Analysis:
North America dominated the global autoimmune hepatitis treatment market in 2017. This can be attributed to the presence of key players, high awareness levels about available treatments, and availability of effective products. In addition, increasing cases of AIH are also contributing towards market growth in this region. For instance, according to a study published by National Institute of Health (NIH), approximately 0.5 million people were diagnosed with AIH between 2000 and 2015 which is around 25% increase from previous estimates between 1990 and 1999 cohort.
Growth Factors:
- Increasing incidence of autoimmune hepatitis
- Growing awareness about autoimmune hepatitis and its treatment options
- Rising demand for better and more effective treatments for autoimmune hepatitis
- Availability of new and innovative therapies for the treatment of autoimmune hepatitis
- increasing research funding for the development of novel therapies for autoimmune hepatitis
Scope Of The Report
Report Attributes
Report Details
Report Title
Autoimmune Hepatitis Treatment Market Research Report
By Type
Table Product, Inject Product, Others
By Application
Hospital, Clinic, Others
By Companies
Gilead Sciences, Inc., Acorda Therapeutics, Inc., Allergan & Novartis, Intercept Pharmaceuticals, Inc., Hightidetx, Shire Plc., NGM Biopharmaceuticals, Inc., EA Pharma, BiomX, CymaBay Therapeutics, Conatus Pharmaceuticals, Inc., Durect Corporation, Sirnaomics, Inc., Shenzhen HighTide Biopharmaceuticals Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
213
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Autoimmune Hepatitis Treatment Market Report Segments:
The global Autoimmune Hepatitis Treatment market is segmented on the basis of:
Types
Table Product, Inject Product, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead Sciences, Inc.
- Acorda Therapeutics, Inc.
- Allergan & Novartis
- Intercept Pharmaceuticals, Inc.
- Hightidetx
- Shire Plc.
- NGM Biopharmaceuticals, Inc.
- EA Pharma
- BiomX
- CymaBay Therapeutics
- Conatus Pharmaceuticals, Inc.
- Durect Corporation
- Sirnaomics, Inc.
- Shenzhen HighTide Biopharmaceuticals Ltd.
Highlights of The Autoimmune Hepatitis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Table Product
- Inject Product
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Autoimmune Hepatitis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Autoimmune hepatitis is a condition in which the bodyu2019s immune system attacks and destroys its own liver cells. Treatment typically includes medications to suppress the immune system and liver transplantation, if necessary.
Some of the major players in the autoimmune hepatitis treatment market are Gilead Sciences, Inc., Acorda Therapeutics, Inc., Allergan & Novartis, Intercept Pharmaceuticals, Inc., Hightidetx, Shire Plc., NGM Biopharmaceuticals, Inc., EA Pharma, BiomX, CymaBay Therapeutics, Conatus Pharmaceuticals, Inc., Durect Corporation, Sirnaomics, Inc., Shenzhen HighTide Biopharmaceuticals Ltd..
The autoimmune hepatitis treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Autoimmune Hepatitis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Autoimmune Hepatitis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Autoimmune Hepatitis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Autoimmune Hepatitis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Autoimmune Hepatitis Treatment Market Size & Forecast, 2018-2028
4.5.1 Autoimmune Hepatitis Treatment Market Size and Y-o-Y Growth
4.5.2 Autoimmune Hepatitis Treatment Market Absolute $ Opportunity
Chapter 5 Global Autoimmune Hepatitis Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Autoimmune Hepatitis Treatment Market Size Forecast by Type
5.2.1 Table Product
5.2.2 Inject Product
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Autoimmune Hepatitis Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Autoimmune Hepatitis Treatment Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Autoimmune Hepatitis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Autoimmune Hepatitis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Autoimmune Hepatitis Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Autoimmune Hepatitis Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Autoimmune Hepatitis Treatment Market Size Forecast by Type
9.6.1 Table Product
9.6.2 Inject Product
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Autoimmune Hepatitis Treatment Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Autoimmune Hepatitis Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Autoimmune Hepatitis Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Autoimmune Hepatitis Treatment Market Size Forecast by Type
10.6.1 Table Product
10.6.2 Inject Product
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Autoimmune Hepatitis Treatment Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Autoimmune Hepatitis Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Autoimmune Hepatitis Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Autoimmune Hepatitis Treatment Market Size Forecast by Type
11.6.1 Table Product
11.6.2 Inject Product
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Autoimmune Hepatitis Treatment Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Autoimmune Hepatitis Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Autoimmune Hepatitis Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Autoimmune Hepatitis Treatment Market Size Forecast by Type
12.6.1 Table Product
12.6.2 Inject Product
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Autoimmune Hepatitis Treatment Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Autoimmune Hepatitis Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Autoimmune Hepatitis Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Autoimmune Hepatitis Treatment Market Size Forecast by Type
13.6.1 Table Product
13.6.2 Inject Product
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Autoimmune Hepatitis Treatment Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Autoimmune Hepatitis Treatment Market: Competitive Dashboard
14.2 Global Autoimmune Hepatitis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gilead Sciences, Inc.
14.3.2 Acorda Therapeutics, Inc.
14.3.3 Allergan & Novartis
14.3.4 Intercept Pharmaceuticals, Inc.
14.3.5 Hightidetx
14.3.6 Shire Plc.
14.3.7 NGM Biopharmaceuticals, Inc.
14.3.8 EA Pharma
14.3.9 BiomX
14.3.10 CymaBay Therapeutics
14.3.11 Conatus Pharmaceuticals, Inc.
14.3.12 Durect Corporation
14.3.13 Sirnaomics, Inc.
14.3.14 Shenzhen HighTide Biopharmaceuticals Ltd.
